Pharmion presents results from several studies of Vidaza in cancer

By Lisa Kerner

Charlotte, N.C., June 7 - Pharmion Corp. reported findings from seven studies of Vidaza (azacitidine for injectable suspension) in hematologic and solid tumor cancers at the 42nd Annual Meeting of the American Society of Clinical Oncology in Atlanta.

The studies of Vidaza included alternative dosing schedules and combination use with other therapies, such as thalidomide, carboplatin and the HDAC inhibitor VPA, according to a company news release.

Vidaza is believed to cause hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow, leading to cell death.

Located in Boulder, Colo., Pharmion acquires and develops products for the treatment of hematology and oncology patients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.